A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

NCT03520959 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

1

Enrollment

INDUSTRY

Sponsor class

Stopped Study was terminated due to sponsor's decision.

Conditions

Synovial Sarcoma
Cancer
Soft Tissue Sarcoma
Sarcoma
Metastatic Sarcoma

Interventions

BIOLOGICAL: LV305
BIOLOGICAL: G305
OTHER: LV305-matching placebo
OTHER: G305-matching placebo

Sponsor

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)